Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $22.10 | Total: $110.50 |
| 1 | 10 | $18.72 | Total: $187.20 |
| 1 | 25 | $15.86 | Total: $396.50 |
| 1 | 50 | $13.52 | Total: $676.00 |
| 1 | 100 | $11.70 | Total: $1,170.00 |
Overview
Enoxaparin sodium is a low-molecular-weight heparin (LMWH) that has recently been approved by the US FDA for use in patients with medically managed ST-segment myocardial infarction (STEMI), or STEMI with subsequent percutaneous coronary intervention (PCI). It binds to and potentiates the action of antithrombin, and inhibits coagulation factors XIa, IXa, Xa and IIa (thrombin), thereby preventing formation of blood clots.
Chemical Properties
| Molecular Formula | C42H59N3Na4O35S2 |
| Molecular Weight | 1322 |
| CAS Numbers | 679809-58-6 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | [Na+].[Na+].[Na+].[Na+].C[C@@H]1[C@@H](NC(C)=O)[C@@H](OC2[C@H](O)[C@@H](O)[C@H](OC3[C@H]4CO[C@H](O4)[C@H](NS([O-])(=O)=O)[C@H]3O)OC2C([O-])=O)O[C@H](CO)[C@H]1O[C@@H]1CC([C@@H](O[C@H]2O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]3OC(=C[C@H](O)[C@H]3O)C([O-])=O)[C@H]( |
Storage and Handling
0C Short Term, -20C Long Term
References
Carter NJ, McCormack PL, Plosker GL. Enoxaparin a review of its use in ST-segment elevation myocardial infarction. Drugs. 2008;68[5] 691-710.